Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
1500 participants
Study Classification
OBSERVATIONAL
Study Start Date
2017-03-25
Study Completion Date
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Frailty is a syndrome in which the accumulation of small, individually insignificant deficits leads to heightened vulnerability to adverse events and predisposes to potential catastrophic decompensation.
Objective of this study is to clarify the underlying genetic and immunological mechanisms responsible of frailty condition focused on: i. nephrosclerosis ageing kidney phenotype related to salt effects on immunosystem, ii. immunological aspect of sarcopenia, iii. psychological disorder related to immunosystem activation, iv. detection of new biomarkers of frailty.
Objective of this study is to clarify the underlying genetic and immunological mechanisms responsible of frailty condition focused on: i. nephrosclerosis ageing kidney phenotype related to salt effects on immunosystem, ii. immunological aspect of sarcopenia, iii. psychological disorder related to immunosystem activation, iv. detection of new biomarkers of frailty.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The cross-sectional, observational cohort study include 1500 subjects (age \>65 years) subdivided in 750 cases and 750 controls according to frailty.
Subjects who met the following criteria are included: 1) older than 65; 2) able to walk 500 m without assistance; 3) a Mini-Mental State Examination (MMSE) score \<18; and 4) no severe health problems (eg, uncontrolled hypertension, recent upper or lower extremity fractures, myocardial infarction within the past 1 year).
According to definition for the 'phenotype' of frailty (cases) is as follows: presence of three or more of the following features:
1. Decreased grip strength
2. Self-reported exhaustion
3. Unintentional weight loss of more than 4.5 kg over the past year
4. Slow walking speed
5. Low physical activity
The investigators select as control subjects with presence of less than 1 criteria . All the control subjects are evaluated by the same protocol than the cases. Subjects will be collected in collaboration with senior housing (RSA) of Milano city, country clubs, social club for elderly, and elderly university. The study will be approved by the Ethics Committee of ASL of Milano city and at individual centers by local ethical committees. All the study participants signed informed consent. At the baseline evaluation, a large amount of data is collected. First, the participants completed a battery of self-reported questionnaires concerning the demographic characteristics, psychosocial adjustment, quality of life, and health condition, in the presence of a trained psychologist in order to clarify any doubts. Second, an expert in physical education and adapted physical activity for older adults administered physical tests. Finally, people with expertise in the eld of ergonomics take anthropometric measurements. Data collection is always carried out in the same order and individually for each participant.
In all the subjects following clinical and laboratoristic data are collected:
1\. Clinical evaluation:
1. Collection of anamnestic data.
2. Blood pressure measurement. Blood pressure is measured by a trained nurse using an authomatic device (OMRON) and an appropriately sized cuff. Readings are obtained after 5 min of seated rest. The mean of 3 blood pressure measurements obtained at 1-min intervals during the medical evaluation is used to define SBP and DBP.
3. Evaluation of kidney function :
a. CKD is defined as a glomerular filtration rate (GFR) lower than 60 mL/min/1.73 m2 or markers of kidney damage, such as albuminuria,for greater than 3 months. A creatinine-based formula is used to estimate GFR, applying Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.
b. Urine analysis and albumin /creatinine and sodium /creatinine ratio urinary excretion.
2\. Physical frailty measure. To identify physically frail older adults, an adapted version of the frailty phenotype of Fried et al is used. Subjects with three or more criteria are classified as frail, those with one or two as prefrail, and those meeting none as robust.
1. Body composition: Height and weight are detected. Bioimpedance analysis (BIA) is a system of evaluation of body composition, able to calculate adjunctive information: total body water (TBW), extra and intracellular water (ECW and ICW), body cell mass (BCM), muscle mass (MM), fat mass (FM), fat free mass (FFM), basal metabolic rate.
2. SPPB: The short physical performance battery (SPPB) is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older people. The scores range from 0 (worst performance) to 12 (best performance).
3. PASE: Physical Activity Scale for the Elderly (PASE) is a brief (5 minutes) and easily scored survey designed specifically to assess physical activity in epidemiological studies of persons age 65 years and older. The PASE score combines information on leisure, household and occupational activity. The PASE assesses the types of activities typically chosen by older adults (walking, recreational activities, exercise, housework, yard work, and caring for others. It uses frequency, duration, and intensity level of activity over the previous week to assign a score, ranging from 0 to 793, with higher scores indicating greater physical activity.
Sarcopenia will be defined as fat-free mass index (FFMI) below the 25th percentile combined with one of the following functional parameter: either an SPPB score ≤8 or a comfortable gait speed \<1.0 m/s.
3\. Psychological test will be used to assess self conditions
1. Mini Mental State Examination (MMSE): The Mini-Mental Stat Examination (MMSE) is a 10-minute measure of cognitive impairment in undeveloped, uneducated, diseased, or very old populations.
2. Geriatric Depression Scale-short form (GDS-15): The Geriatric Depression Scale (GDS) is a 15- item self-report validated measure for rating depression in elderly adults. Additionally, the GDS is sensitive to depression among elderly adults suffering from mild to moderate dementia and elderly adults with physical illnesses by excluding questions pertaining to somatic complaints and cognitive dimension of depression. In this scale, a score of 6 or higher may be indicative of depression and must be evaluated jointly with patient's clinical data.
3. SF-36 Medical Outcomes Study (MOS) 36-item Short Form Health Survey: This instrument should capture both mental and physical aspects of health. The 36 6-likert item assess health across eight domains, namely bodily pain, general health perceptions, mental health, physical functioning, role limitations due to emotional health problems, role limitations due to physical health problems, social functioning, and vitality. All items use categorical response options (range: 2-6 options). Two component summary scores for physical and mental health (MPS and MCS, respectively) can also be calculated.
4\. Laboratory Methods
1. Genotyping. OpenArray technology (ThermoFisher) for genetic characterization of Single Nucleotide Polymorphisms (SNPs), based on TaqMan chemistry. DNA will be used for genotyping of genetic variants in loci for Klotho (KL) gene, Adducins (ADD1, ADD2 and ADD3) and EO synthesis (LSS, HSD3B1), metabolism (CYP11A1, ABCB1), and activity (SLC8A1, SIK1) genes, and for immunological pathway (TLR4, HMGB1, IL6, IL1).
2. Biochemical measurements.
1. Endogenous Ouabain measurement
2. Plasma Klotho measurement.
3. Immunological determinations. Simultaneous assessment of serum concentrations of epidermal growth factor (EGF), fibroblast growth factor 2 (FGF2), FMS-like tyrosine kinase 3 ligand (Flt-3L), granulocyte colony-stimulating factor (G-CSF), granulocyte-monocyte colonystimulating factor (GM-CSF), interferon-α2 (IFN-α2), INF-γ, IL-10, IL-15, IL-17, IL-1β, IL-2, IL-6, IL-8, INF-γ inducible protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1β (MIP-1 β), platelet-derived growth factor-AA (PDGF-AA), soluble CD40 ligand (sCD40L), transforming growth factor alpha (TGF-α), TNF-α and vascular endothelial growth factor (VEGF).
Subjects who met the following criteria are included: 1) older than 65; 2) able to walk 500 m without assistance; 3) a Mini-Mental State Examination (MMSE) score \<18; and 4) no severe health problems (eg, uncontrolled hypertension, recent upper or lower extremity fractures, myocardial infarction within the past 1 year).
According to definition for the 'phenotype' of frailty (cases) is as follows: presence of three or more of the following features:
1. Decreased grip strength
2. Self-reported exhaustion
3. Unintentional weight loss of more than 4.5 kg over the past year
4. Slow walking speed
5. Low physical activity
The investigators select as control subjects with presence of less than 1 criteria . All the control subjects are evaluated by the same protocol than the cases. Subjects will be collected in collaboration with senior housing (RSA) of Milano city, country clubs, social club for elderly, and elderly university. The study will be approved by the Ethics Committee of ASL of Milano city and at individual centers by local ethical committees. All the study participants signed informed consent. At the baseline evaluation, a large amount of data is collected. First, the participants completed a battery of self-reported questionnaires concerning the demographic characteristics, psychosocial adjustment, quality of life, and health condition, in the presence of a trained psychologist in order to clarify any doubts. Second, an expert in physical education and adapted physical activity for older adults administered physical tests. Finally, people with expertise in the eld of ergonomics take anthropometric measurements. Data collection is always carried out in the same order and individually for each participant.
In all the subjects following clinical and laboratoristic data are collected:
1\. Clinical evaluation:
1. Collection of anamnestic data.
2. Blood pressure measurement. Blood pressure is measured by a trained nurse using an authomatic device (OMRON) and an appropriately sized cuff. Readings are obtained after 5 min of seated rest. The mean of 3 blood pressure measurements obtained at 1-min intervals during the medical evaluation is used to define SBP and DBP.
3. Evaluation of kidney function :
a. CKD is defined as a glomerular filtration rate (GFR) lower than 60 mL/min/1.73 m2 or markers of kidney damage, such as albuminuria,for greater than 3 months. A creatinine-based formula is used to estimate GFR, applying Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.
b. Urine analysis and albumin /creatinine and sodium /creatinine ratio urinary excretion.
2\. Physical frailty measure. To identify physically frail older adults, an adapted version of the frailty phenotype of Fried et al is used. Subjects with three or more criteria are classified as frail, those with one or two as prefrail, and those meeting none as robust.
1. Body composition: Height and weight are detected. Bioimpedance analysis (BIA) is a system of evaluation of body composition, able to calculate adjunctive information: total body water (TBW), extra and intracellular water (ECW and ICW), body cell mass (BCM), muscle mass (MM), fat mass (FM), fat free mass (FFM), basal metabolic rate.
2. SPPB: The short physical performance battery (SPPB) is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older people. The scores range from 0 (worst performance) to 12 (best performance).
3. PASE: Physical Activity Scale for the Elderly (PASE) is a brief (5 minutes) and easily scored survey designed specifically to assess physical activity in epidemiological studies of persons age 65 years and older. The PASE score combines information on leisure, household and occupational activity. The PASE assesses the types of activities typically chosen by older adults (walking, recreational activities, exercise, housework, yard work, and caring for others. It uses frequency, duration, and intensity level of activity over the previous week to assign a score, ranging from 0 to 793, with higher scores indicating greater physical activity.
Sarcopenia will be defined as fat-free mass index (FFMI) below the 25th percentile combined with one of the following functional parameter: either an SPPB score ≤8 or a comfortable gait speed \<1.0 m/s.
3\. Psychological test will be used to assess self conditions
1. Mini Mental State Examination (MMSE): The Mini-Mental Stat Examination (MMSE) is a 10-minute measure of cognitive impairment in undeveloped, uneducated, diseased, or very old populations.
2. Geriatric Depression Scale-short form (GDS-15): The Geriatric Depression Scale (GDS) is a 15- item self-report validated measure for rating depression in elderly adults. Additionally, the GDS is sensitive to depression among elderly adults suffering from mild to moderate dementia and elderly adults with physical illnesses by excluding questions pertaining to somatic complaints and cognitive dimension of depression. In this scale, a score of 6 or higher may be indicative of depression and must be evaluated jointly with patient's clinical data.
3. SF-36 Medical Outcomes Study (MOS) 36-item Short Form Health Survey: This instrument should capture both mental and physical aspects of health. The 36 6-likert item assess health across eight domains, namely bodily pain, general health perceptions, mental health, physical functioning, role limitations due to emotional health problems, role limitations due to physical health problems, social functioning, and vitality. All items use categorical response options (range: 2-6 options). Two component summary scores for physical and mental health (MPS and MCS, respectively) can also be calculated.
4\. Laboratory Methods
1. Genotyping. OpenArray technology (ThermoFisher) for genetic characterization of Single Nucleotide Polymorphisms (SNPs), based on TaqMan chemistry. DNA will be used for genotyping of genetic variants in loci for Klotho (KL) gene, Adducins (ADD1, ADD2 and ADD3) and EO synthesis (LSS, HSD3B1), metabolism (CYP11A1, ABCB1), and activity (SLC8A1, SIK1) genes, and for immunological pathway (TLR4, HMGB1, IL6, IL1).
2. Biochemical measurements.
1. Endogenous Ouabain measurement
2. Plasma Klotho measurement.
3. Immunological determinations. Simultaneous assessment of serum concentrations of epidermal growth factor (EGF), fibroblast growth factor 2 (FGF2), FMS-like tyrosine kinase 3 ligand (Flt-3L), granulocyte colony-stimulating factor (G-CSF), granulocyte-monocyte colonystimulating factor (GM-CSF), interferon-α2 (IFN-α2), INF-γ, IL-10, IL-15, IL-17, IL-1β, IL-2, IL-6, IL-8, INF-γ inducible protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1β (MIP-1 β), platelet-derived growth factor-AA (PDGF-AA), soluble CD40 ligand (sCD40L), transforming growth factor alpha (TGF-α), TNF-α and vascular endothelial growth factor (VEGF).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Aging
Frailty
Hypertension
CKD
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
aging
Klotho
Hypertension
physical activity
frailty
sarcopenia
body composition
CKD
cognitive impairment
depression
inflammation
citokine
adducin
ouabain
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Frailty Group
The 'phenotype' of frailty (cases) is defined as follows: presence of three or more of the following features:
1. Decreased grip strength
2. Self-reported exhaustion
3. Unintentional weight loss of more than 4.5 kg over the past year
4. Slow walking speed
5. Low physical activity
No interventions assigned to this group
Non-Frailty Group
The 'phenotype' of non-frailty (control) is defined as follows: presence of less than three of the following features:
1. Decreased grip strength
2. Self-reported exhaustion
3. Unintentional weight loss of more than 4.5 kg over the past year
4. Slow walking speed
5. Low physical activity
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 65 years
* Male and female patients
* Patients able to walk \> 500 m without assistance
* MMSE \< 18
* No severe health problems (Uncontrolled hypertension, recent upper or lower extremity fractures, myocardial infarction within the past 1 year).
* Male and female patients
* Patients able to walk \> 500 m without assistance
* MMSE \< 18
* No severe health problems (Uncontrolled hypertension, recent upper or lower extremity fractures, myocardial infarction within the past 1 year).
Exclusion Criteria
* Severe cardiological or pulmonary disease (NYHA IV, Gold IV)
* Intracranial interventions
* Dying patients (palliative situation)
* Not enough language skills
* Non-consenting patients
* Participation in another prospective intervention study for study inclusion or throughout the study period.
* Intracranial interventions
* Dying patients (palliative situation)
* Not enough language skills
* Non-consenting patients
* Participation in another prospective intervention study for study inclusion or throughout the study period.
Minimum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cariplo Foundation
UNKNOWN
Sponsor Role
collaborator
IRCCS San Raffaele
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paolo Manunta
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paolo Manunta, PhDMD
Role: PRINCIPAL_INVESTIGATOR
IRCCS San Raffaele
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Ospedale San Raffaele
Milan, , Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chiara Lanzani, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011 Jan;12(1):56-68. doi: 10.1038/nrg2918.
Reference Type
BACKGROUND
Barabasi AL. Network medicine--from obesity to the "diseasome". N Engl J Med. 2007 Jul 26;357(4):404-7. doi: 10.1056/NEJMe078114. Epub 2007 Jul 25. No abstract available.
Reference Type
BACKGROUND
Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. Proc Natl Acad Sci U S A. 2007 May 22;104(21):8685-90. doi: 10.1073/pnas.0701361104. Epub 2007 May 14.
Reference Type
BACKGROUND
Kyle UG, Genton L, Hans D, Karsegard VL, Michel JP, Slosman DO, Pichard C. Total body mass, fat mass, fat-free mass, and skeletal muscle in older people: cross-sectional differences in 60-year-old persons. J Am Geriatr Soc. 2001 Dec;49(12):1633-40. doi: 10.1046/j.1532-5415.2001.t01-1-49272.x.
Reference Type
BACKGROUND
Melton LJ 3rd, Riggs BL, Achenbach SJ, Amin S, Camp JJ, Rouleau PA, Robb RA, Oberg AL, Khosla S. Does reduced skeletal loading account for age-related bone loss? J Bone Miner Res. 2006 Dec;21(12):1847-55. doi: 10.1359/jbmr.060908.
Reference Type
BACKGROUND
Newman AB, Haggerty CL, Goodpaster B, Harris T, Kritchevsky S, Nevitt M, Miles TP, Visser M; Health Aging And Body Composition Research Group. Strength and muscle quality in a well-functioning cohort of older adults: the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2003 Mar;51(3):323-30. doi: 10.1046/j.1532-5415.2003.51105.x.
Reference Type
BACKGROUND
Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):253-9. doi: 10.1007/s13539-014-0161-y. Epub 2014 Oct 22.
Reference Type
BACKGROUND
Abellan van Kan G. Epidemiology and consequences of sarcopenia. J Nutr Health Aging. 2009 Oct;13(8):708-12. doi: 10.1007/s12603-009-0201-z.
Reference Type
BACKGROUND
Janssen I. The epidemiology of sarcopenia. Clin Geriatr Med. 2011 Aug;27(3):355-63. doi: 10.1016/j.cger.2011.03.004. Epub 2011 May 14.
Reference Type
BACKGROUND
Liu CK, Leng X, Hsu FC, Kritchevsky SB, Ding J, Earnest CP, Ferrucci L, Goodpaster BH, Guralnik JM, Lenchik L, Pahor M, Fielding RA. The impact of sarcopenia on a physical activity intervention: the Lifestyle Interventions and Independence for Elders Pilot Study (LIFE-P). J Nutr Health Aging. 2014 Jan;18(1):59-64. doi: 10.1007/s12603-013-0369-0.
Reference Type
BACKGROUND
Muscaritoli M, Lucia S, Molfino A. Sarcopenia in critically ill patients: the new pandemia. Minerva Anestesiol. 2013 Jul;79(7):771-7. Epub 2013 Jan 31.
Reference Type
BACKGROUND
Kalinkovich A, Livshits G. Sarcopenia--The search for emerging biomarkers. Ageing Res Rev. 2015 Jul;22:58-71. doi: 10.1016/j.arr.2015.05.001. Epub 2015 May 8.
Reference Type
BACKGROUND
Glassock RJ, Rule AD: The kidney in aging. In Davison AM, Cameron S, Grunfeld J-P, Ponticelli C (eds): Oxford Textbook of Clinical Nephrology, ed. 3, Oxford, Oxford University press, (2015
Reference Type
BACKGROUND
Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int. 2012 Aug;82(3):270-7. doi: 10.1038/ki.2012.65. Epub 2012 Mar 21.
Reference Type
BACKGROUND
Wang X, Vrtiska TJ, Avula RT, Walters LR, Chakkera HA, Kremers WK, Lerman LO, Rule AD. Age, kidney function, and risk factors associate differently with cortical and medullary volumes of the kidney. Kidney Int. 2014 Mar;85(3):677-85. doi: 10.1038/ki.2013.359. Epub 2013 Sep 25.
Reference Type
BACKGROUND
Roeder SS, Stefanska A, Eng DG, Kaverina N, Sunseri MW, McNicholas BA, Rabinovitch P, Engel FB, Daniel C, Amann K, Lichtnekert J, Pippin JW, Shankland SJ. Changes in glomerular parietal epithelial cells in mouse kidneys with advanced age. Am J Physiol Renal Physiol. 2015 Jul 15;309(2):F164-78. doi: 10.1152/ajprenal.00144.2015. Epub 2015 May 27.
Reference Type
BACKGROUND
Shankland SJ, Anders HJ, Romagnani P. Glomerular parietal epithelial cells in kidney physiology, pathology, and repair. Curr Opin Nephrol Hypertens. 2013 May;22(3):302-9. doi: 10.1097/MNH.0b013e32835fefd4.
Reference Type
BACKGROUND
Mekli K, Marshall A, Nazroo J, Vanhoutte B, Pendleton N. Genetic variant of Interleukin-18 gene is associated with the Frailty Index in the English Longitudinal Study of Ageing. Age Ageing. 2015 Nov;44(6):938-42. doi: 10.1093/ageing/afv122. Epub 2015 Sep 22.
Reference Type
BACKGROUND
Tripodi G, Citterio L, Kouznetsova T, Lanzani C, Florio M, Modica R, Messaggio E, Hamlyn JM, Zagato L, Bianchi G, Staessen JA, Manunta P. Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain. Am J Hypertens. 2009 Apr;22(4):357-63. doi: 10.1038/ajh.2009.3. Epub 2009 Feb 5.
Reference Type
BACKGROUND
Manunta P, Messaggio E, Casamassima N, Gatti G, Carpini SD, Zagato L, Hamlyn JM. Endogenous ouabain in renal Na(+) handling and related diseases. Biochim Biophys Acta. 2010 Dec;1802(12):1214-8. doi: 10.1016/j.bbadis.2010.03.001. Epub 2010 Mar 11.
Reference Type
BACKGROUND
Citterio L, Lanzani C, Manunta P, Bianchi G. Genetics of primary hypertension: the clinical impact of adducin polymorphisms. Biochim Biophys Acta. 2010 Dec;1802(12):1285-98. doi: 10.1016/j.bbadis.2010.03.014. Epub 2010 Apr 8.
Reference Type
BACKGROUND
Chen X, Mao G, Leng SX. Frailty syndrome: an overview. Clin Interv Aging. 2014 Mar 19;9:433-41. doi: 10.2147/CIA.S45300. eCollection 2014.
Reference Type
BACKGROUND
Wade B, Abais-Battad JM, Mattson DL. Role of immune cells in salt-sensitive hypertension and renal injury. Curr Opin Nephrol Hypertens. 2016 Jan;25(1):22-7. doi: 10.1097/MNH.0000000000000183.
Reference Type
BACKGROUND
Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007 Oct 1;204(10):2449-60. doi: 10.1084/jem.20070657. Epub 2007 Sep 17.
Reference Type
BACKGROUND
Youn JC, Yu HT, Lim BJ, Koh MJ, Lee J, Chang DY, Choi YS, Lee SH, Kang SM, Jang Y, Yoo OJ, Shin EC, Park S. Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013 Jul;62(1):126-33. doi: 10.1161/HYPERTENSIONAHA.113.00689. Epub 2013 May 28.
Reference Type
BACKGROUND
Kuro-o M. Klotho and aging. Biochim Biophys Acta. 2009 Oct;1790(10):1049-58. doi: 10.1016/j.bbagen.2009.02.005. Epub 2009 Feb 20.
Reference Type
BACKGROUND
Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev. 2009 Jan;8(1):43-51. doi: 10.1016/j.arr.2008.10.002. Epub 2008 Oct 31.
Reference Type
BACKGROUND
Di Bona D, Accardi G, Virruso C, Candore G, Caruso C. Association of Klotho polymorphisms with healthy aging: a systematic review and meta-analysis. Rejuvenation Res. 2014 Apr;17(2):212-6. doi: 10.1089/rej.2013.1523. Epub 2014 Apr 11.
Reference Type
BACKGROUND
Mengel-From J, Soerensen M, Nygaard M, McGue M, Christensen K, Christiansen L. Genetic Variants in KLOTHO Associate With Cognitive Function in the Oldest Old Group. J Gerontol A Biol Sci Med Sci. 2016 Sep;71(9):1151-9. doi: 10.1093/gerona/glv163. Epub 2015 Sep 24.
Reference Type
BACKGROUND
Shardell M, Semba RD, Rosano C, Kalyani RR, Bandinelli S, Chia CW, Ferrucci L. Plasma Klotho and Cognitive Decline in Older Adults: Findings From the InCHIANTI Study. J Gerontol A Biol Sci Med Sci. 2016 May;71(5):677-82. doi: 10.1093/gerona/glv140. Epub 2015 Aug 21.
Reference Type
BACKGROUND
Hsu YH, Liang CK, Chou MY, Liao MC, Lin YT, Chen LK, Lo YK. Association of cognitive impairment, depressive symptoms and sarcopenia among healthy older men in the veterans retirement community in southern Taiwan: a cross-sectional study. Geriatr Gerontol Int. 2014 Feb;14 Suppl 1:102-8. doi: 10.1111/ggi.12221.
Reference Type
BACKGROUND
Bremmer MA, Beekman AT, Deeg DJ, Penninx BW, Dik MG, Hack CE, Hoogendijk WJ. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord. 2008 Mar;106(3):249-55. doi: 10.1016/j.jad.2007.07.002. Epub 2007 Aug 22.
Reference Type
BACKGROUND
Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S, Ferrucci L, Harris T, Pahor M. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry. 2003 Sep 1;54(5):566-72. doi: 10.1016/s0006-3223(02)01811-5.
Reference Type
BACKGROUND
Tiemeier H, Hofman A, van Tuijl HR, Kiliaan AJ, Meijer J, Breteler MM. Inflammatory proteins and depression in the elderly. Epidemiology. 2003 Jan;14(1):103-7. doi: 10.1097/00001648-200301000-00025.
Reference Type
BACKGROUND
Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry. 1999;60 Suppl 20:9-15.
Reference Type
BACKGROUND
Liu M, Li Y, Citterio L, Huang QF, Zeng WF, Sheng CS, Wei FF, Dong Q, Li GL, Kang YY, Zhang L, Xu TY, Li JJ, Song J, Manunta P, Wang JG. A functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in Chinese. Am J Hypertens. 2013 Dec;26(12):1428-36. doi: 10.1093/ajh/hpt126. Epub 2013 Aug 7.
Reference Type
BACKGROUND
Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LM. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol. 2000 Feb 1;103(1):97-102. doi: 10.1016/s0165-5728(99)00226-x.
Reference Type
BACKGROUND
Siu PM, Pistilli EE, Alway SE. Age-dependent increase in oxidative stress in gastrocnemius muscle with unloading. J Appl Physiol (1985). 2008 Dec;105(6):1695-705. doi: 10.1152/japplphysiol.90800.2008. Epub 2008 Sep 18.
Reference Type
BACKGROUND
Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci. 2010 Apr 12;11(4):1509-26. doi: 10.3390/ijms11041509.
Reference Type
BACKGROUND
Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004 Mar;59(3):255-63. doi: 10.1093/gerona/59.3.m255.
Reference Type
BACKGROUND
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. doi: 10.1093/gerona/56.3.m146.
Reference Type
BACKGROUND
Zuidema S, Koopmans R, Verhey F. Prevalence and predictors of neuropsychiatric symptoms in cognitively impaired nursing home patients. J Geriatr Psychiatry Neurol. 2007 Mar;20(1):41-9. doi: 10.1177/0891988706292762.
Reference Type
BACKGROUND
Wada T, Ishine M, Sakagami T, Kita T, Okumiya K, Mizuno K, Rambo TA, Matsubayashi K. Depression, activities of daily living, and quality of life of community-dwelling elderly in three Asian countries: Indonesia, Vietnam, and Japan. Arch Gerontol Geriatr. 2005 Nov-Dec;41(3):271-80. doi: 10.1016/j.archger.2005.03.003. Epub 2005 Jun 24.
Reference Type
BACKGROUND
Strawbridge WJ, Shema SJ, Balfour JL, Higby HR, Kaplan GA. Antecedents of frailty over three decades in an older cohort. J Gerontol B Psychol Sci Soc Sci. 1998 Jan;53(1):S9-16. doi: 10.1093/geronb/53b.1.s9.
Reference Type
BACKGROUND
Zhou X, Crook MF, Sharif-Rodriguez W, Zhu Y, Ruben Z, Pan Y, Urosevic-Price O, Wang L, Flattery AM, Forrest G, Szeto D, Zhao H, Roy S, Forrest MJ. Chronic antagonism of the mineralocorticoid receptor ameliorates hypertension and end organ damage in a rodent model of salt-sensitive hypertension. Clin Exp Hypertens. 2011;33(8):538-47. doi: 10.3109/10641963.2011.566956. Epub 2011 Sep 27.
Reference Type
BACKGROUND
Esposito A, Campana L, Palmisano A, De Cobelli F, Canu T, Santarella F, Colantoni C, Monno A, Vezzoli M, Pezzetti G, Manfredi AA, Rovere-Querini P, Del Maschio A. Magnetic resonance imaging at 7T reveals common events in age-related sarcopenia and in the homeostatic response to muscle sterile injury. PLoS One. 2013;8(3):e59308. doi: 10.1371/journal.pone.0059308. Epub 2013 Mar 12.
Reference Type
BACKGROUND
Georgakis MK, Papadopoulos FC, Protogerou AD, Pagonari I, Sarigianni F, Biniaris-Georgallis SI, Kalogirou EIota, Thomopoulos TP, Kapaki E, Papageorgiou C, Papageorgiou SG, Tousoulis D, Petridou ET. Comorbidity of Cognitive Impairment and Late-Life Depression Increase Mortality: Results From a Cohort of Community-Dwelling Elderly Individuals in Rural Greece. J Geriatr Psychiatry Neurol. 2016 Jul;29(4):195-204. doi: 10.1177/0891988716632913. Epub 2016 Feb 25.
Reference Type
BACKGROUND
Saracli O, Akca AS, Atasoy N, Onder O, Senormanci O, Kaygisiz I, Atik L. The Relationship between Quality of Life and Cognitive Functions, Anxiety and Depression among Hospitalized Elderly Patients. Clin Psychopharmacol Neurosci. 2015 Aug 31;13(2):194-200. doi: 10.9758/cpn.2015.13.2.194.
Reference Type
BACKGROUND
Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Galvez BG, Perrotta C, Monopoli A, Sanvito F, Bottinelli R, Ongini E, Cossu G, Clementi E. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):264-9. doi: 10.1073/pnas.0608277104. Epub 2006 Dec 20.
Reference Type
BACKGROUND
Miglietta D, De Palma C, Sciorati C, Vergani B, Pisa V, Villa A, Ongini E, Clementi E. Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy. Orphanet J Rare Dis. 2015 Aug 22;10:101. doi: 10.1186/s13023-015-0311-0.
Reference Type
BACKGROUND
Touvier T, De Palma C, Rigamonti E, Scagliola A, Incerti E, Mazelin L, Thomas JL, D'Antonio M, Politi L, Schaeffer L, Clementi E, Brunelli S. Muscle-specific Drp1 overexpression impairs skeletal muscle growth via translational attenuation. Cell Death Dis. 2015 Feb 26;6(2):e1663. doi: 10.1038/cddis.2014.595.
Reference Type
BACKGROUND
Willmann R, De Luca A, Benatar M, Grounds M, Dubach J, Raymackers JM, Nagaraju K; TREAT-NMD Neuromuscular Network. Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul Disord. 2012 Jan;22(1):43-9. doi: 10.1016/j.nmd.2011.04.012. Epub 2011 Jul 6.
Reference Type
BACKGROUND
De Palma C, Morisi F, Cheli S, Pambianco S, Cappello V, Vezzoli M, Rovere-Querini P, Moggio M, Ripolone M, Francolini M, Sandri M, Clementi E. Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis. 2012 Nov 15;3(11):e418. doi: 10.1038/cddis.2012.159.
Reference Type
BACKGROUND
De Palma C, Morisi F, Pambianco S, Assi E, Touvier T, Russo S, Perrotta C, Romanello V, Carnio S, Cappello V, Pellegrino P, Moscheni C, Bassi MT, Sandri M, Cervia D, Clementi E. Deficient nitric oxide signalling impairs skeletal muscle growth and performance: involvement of mitochondrial dysregulation. Skelet Muscle. 2014 Dec 12;4(1):22. doi: 10.1186/s13395-014-0022-6. eCollection 2014.
Reference Type
BACKGROUND
De Palma C, Falcone S, Pisoni S, Cipolat S, Panzeri C, Pambianco S, Pisconti A, Allevi R, Bassi MT, Cossu G, Pozzan T, Moncada S, Scorrano L, Brunelli S, Clementi E. Nitric oxide inhibition of Drp1-mediated mitochondrial fission is critical for myogenic differentiation. Cell Death Differ. 2010 Nov;17(11):1684-96. doi: 10.1038/cdd.2010.48. Epub 2010 May 14.
Reference Type
BACKGROUND
Cordani N, Pisa V, Pozzi L, Sciorati C, Clementi E. Nitric oxide controls fat deposition in dystrophic skeletal muscle by regulating fibro-adipogenic precursor differentiation. Stem Cells. 2014 Apr;32(4):874-85. doi: 10.1002/stem.1587.
Reference Type
BACKGROUND
Sciorati C, Buono R, Azzoni E, Casati S, Ciuffreda P, D'Angelo G, Cattaneo D, Brunelli S, Clementi E. Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Br J Pharmacol. 2010 Jul;160(6):1550-60. doi: 10.1111/j.1476-5381.2010.00809.x.
Reference Type
BACKGROUND
Sciorati C, Staszewsky L, Zambelli V, Russo I, Salio M, Novelli D, Di Grigoli G, Moresco RM, Clementi E, Latini R. Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure. Pharmacol Res. 2013 Jul;73:35-43. doi: 10.1016/j.phrs.2013.04.009. Epub 2013 May 1.
Reference Type
BACKGROUND
D'Angelo MG, Gandossini S, Martinelli Boneschi F, Sciorati C, Bonato S, Brighina E, Comi GP, Turconi AC, Magri F, Stefanoni G, Brunelli S, Bresolin N, Cattaneo D, Clementi E. Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol Res. 2012 Apr;65(4):472-9. doi: 10.1016/j.phrs.2012.01.006. Epub 2012 Jan 25.
Reference Type
BACKGROUND
Cossu MV, Cattaneo D, Fucile S, Pellegrino P, Baldelli S, Cozzi V, Capetti A, Clementi E. Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers. Drug Des Devel Ther. 2014 May 2;8:411-9. doi: 10.2147/DDDT.S58803. eCollection 2014.
Reference Type
BACKGROUND
Sciorati C, Miglietta D, Buono R, Pisa V, Cattaneo D, Azzoni E, Brunelli S, Clementi E. A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. Pharmacol Res. 2011 Sep;64(3):210-7. doi: 10.1016/j.phrs.2011.05.003. Epub 2011 May 12.
Reference Type
BACKGROUND
Campana L, Santarella F, Esposito A, Maugeri N, Rigamonti E, Monno A, Canu T, Del Maschio A, Bianchi ME, Manfredi AA, Rovere-Querini P. Leukocyte HMGB1 is required for vessel remodeling in regenerating muscles. J Immunol. 2014 Jun 1;192(11):5257-64. doi: 10.4049/jimmunol.1300938. Epub 2014 Apr 21.
Reference Type
BACKGROUND
Castiglioni A, Corna G, Rigamonti E, Basso V, Vezzoli M, Monno A, Almada AE, Mondino A, Wagers AJ, Manfredi AA, Rovere-Querini P. FOXP3+ T Cells Recruited to Sites of Sterile Skeletal Muscle Injury Regulate the Fate of Satellite Cells and Guide Effective Tissue Regeneration. PLoS One. 2015 Jun 3;10(6):e0128094. doi: 10.1371/journal.pone.0128094. eCollection 2015.
Reference Type
BACKGROUND
Lukaski HC. Evolution of bioimpedance: a circuitous journey from estimation of physiological function to assessment of body composition and a return to clinical research. Eur J Clin Nutr. 2013 Jan;67 Suppl 1:S2-9. doi: 10.1038/ejcn.2012.149.
Reference Type
BACKGROUND
Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available.
Reference Type
BACKGROUND
Yesavage, J.A., Sheikh, J.I.: 9/Geriatric Depression Scale (GDS). Clinical Gerontologist. 5, 165-173 (1986).
Reference Type
BACKGROUND
Burke WJ, Roccaforte WH, Wengel SP. The short form of the Geriatric Depression Scale: a comparison with the 30-item form. J Geriatr Psychiatry Neurol. 1991 Jul-Sep;4(3):173-8. doi: 10.1177/089198879100400310.
Reference Type
BACKGROUND
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.
Reference Type
BACKGROUND
Ware J, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston, MA: The Health Institute, New England Medical Centre (1994).
Reference Type
BACKGROUND
Ware JE. SF-36 Health Survey. Manual and interpretation guide. The Health Institute, New England Medical Centre. Boston, MA. 2nd ed., Nimrod Press (1997)
Reference Type
BACKGROUND
Haywood KL, Garratt AM, Schmidt LJ, Mackintosh AE, Fitzpatrick R. Health Status and Quality of Life in Older People: a Structured Review of Patient-reported Health Instruments Report from the Patient- reported Health Instruments Group (formerly the Patient-assessed Health Outcomes Programme) to the Department of Health (2004).
Reference Type
BACKGROUND
Irvine D, O'Brien-Pallas LL, Murray M, Cockerill R, Sidani S, Laurie-Shaw B, Lochhaas-Gerlach J. The reliability and validity of two health status measures for evaluating outcomes of home care nursing. Res Nurs Health. 2000 Feb;23(1):43-54. doi: 10.1002/(sici)1098-240x(200002)23:13.0.co;2-k.
Reference Type
BACKGROUND
Osborne RH, Hawthorne G, Lew EA, Gray LC. Quality of life assessment in the community-dwelling elderly: validation of the Assessment of Quality of Life (AQoL) Instrument and comparison with the SF-36. J Clin Epidemiol. 2003 Feb;56(2):138-47. doi: 10.1016/s0895-4356(02)00601-7.
Reference Type
BACKGROUND
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.
Reference Type
BACKGROUND
Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994 Mar;49(2):M85-94. doi: 10.1093/geronj/49.2.m85.
Reference Type
BACKGROUND
Vahlberg B, Zetterberg L, Lindmark B, Hellstrom K, Cederholm T. Functional performance, nutritional status, and body composition in ambulant community-dwelling individuals 1-3 years after suffering from a cerebral infarction or intracerebral bleeding. BMC Geriatr. 2016 Feb 19;16:48. doi: 10.1186/s12877-016-0226-1.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FRASNET
Identifier Type: -
Identifier Source: org_study_id